Tag: Corporate

(Oslo, 22. juli 2025) – Statkraft leverte sterkt driftsresultat i andre kvartal 2025, tross lavere priser, spesielt i de nordlige prisområdene i Norge og Sverige. Resultatet ble negativt påvirket av nedskrivninger, hovedsakelig på grunn av forventinger om lavere kraftpriser i enkelte regioner, samt valutaeffekter. Statkraft refokuserer for fortsatt lønnsom vekst.

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

(Oslo, Norway, 22 July 2025) – Statkraft delivered strong operational performance in the second quarter of 2025, despite lower prices, especially in the northern price areas of Norway and Sweden. Net results were negatively impacted by impairments, mostly due to lower estimated future power prices in certain regions, and currency effects. Statkraft continues to refocus for profitable growth.

KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, enkelt-dosis chikungunyavaccinekandidat, CHIKV VLP, til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. Dermed starter myndighedernes standardgennemgang, hvilket potentielt understøtter godkendelse af vaccinen i første halvår 2026.

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI^® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

SAN FRANCISCO, July 21, 2025 (GLOBE NEWSWIRE) -- Healthcare giant Centene Corporation (NYSE: CNC), a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934.

HOUSTON and TOKYO, July 21, 2025 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (including its subsidiaries and affiliates, “Par Pacific”), Mitsubishi Corporation (“Mitsubishi”), and ENEOS Corporation ("ENEOS”) today announced the signing of definitive agreements to establish Hawaii Renewables, LLC (“Hawaii Renewables”), a joint venture to produce renewable fuels at Par Pacific’s refinery in Kapolei Hawaii. Mitsubishi and ENEOS will form Alohi Renewable Energy, LLC, which will acquire a 36.5% equity stake in Hawaii Renewables in exchange for cash consideration of $100 million. Par Pacific will retain the remaining interest and lead the project’s execution and operations through its affiliate, Par Hawaii Refining, LLC. The project’s attractive capital cost, along with its operating and distribution cost advantages, are key differentiators.